title: [Novel therapeutic possibilities in systemic lupus erythematosus].
abstract: Systemic lupus erythematosus (SLE) is an autoimmune disorder involving different organs and organ systems with consequent characteristic clinical and serologic symptoms. Despite of the improvement in lupus survival, approximately 10-20% of patients do not respond to traditional immune suppressive therapies. Relapses are more frequent; e.g. after cyclophosphamide therapy diffuse proliferative nephritis flares in 1/3 of patients. Different immune competent cells and inflammatory mediators participate in the pathogenesis of SLE involving both the adaptive and innate immunity. Several pathogenic elements and mechanisms may serve as therapeutic targets, consequently. Authors summarize novel therapeutic possibilities and their mechanisms regarding the pathogenesis of SLE. Immune modulation of B and T cells, co-stimulatory pathways, cytokine network, soluble mediators and autologous hemopoietic stem cell transplantation are discussed.
authors.affiliation: Országos Reumatológiai és Fizioterápiás Intézet, Budapest.
authors.forename: Anna
authors.initials: A
authors.lastname: Bazsó
authors.forename: Gyula
authors.initials: G
authors.lastname: Poór
authors.forename: Péter
authors.initials: P
authors.lastname: Gergely
authors.forename: Emese
authors.initials: E
authors.lastname: Kiss
mesh_terms: D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology; D016207:Cytokines / Q000187:drug effects / Q000276:immunology; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D008180:Lupus Erythematosus, Systemic / Q000276:immunology* / Q000601:surgery / Q000628:therapy*; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D014182:Transplantation, Autologous
chemical_list: D016207:Cytokines; D016756:Immunoglobulins, Intravenous